Osteonecrosis: An emerging complication of intensive chemotherapy for childhood acute lymphoblastic leukemia

Maurizio Aricò, Marie France Pinta Boccalatte, Daniela Silvestri, Elena Barisone, Chiara Messina, Robert Chiesa, Nicola Santoro, Paolo Tamaro, Alma Lippi, Domenico Gallisai, Giuseppe Basso, Giulio De Rossi

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

Background and Objectives. Osteonecrosis (ON) is a potentially disabling complication of combination chemotherapy including high doses of steroids. The incidence and main risk factors for symptomatic ON have been investigated in a large group of children treated with high-dose steroids, prednisone and dexamethasone for childhood acute lymphoblastic leukemia (ALL). Design and Methods. From May 1995 to December 1999, 1421 patients <18 years old, with newly diagnosed non-B ALL, were registered in the AIEOP-ALL 95 study. Their data were reviewed to identify patients who developed symptomatic ON. For those who were positively identified additional data were requested concerning ON-related symptoms, treatment and outcome. Results. Overall, 15 of the 1421 patients developed symptomatic ON (1.1%) in a total of 29 sites. The estimated 5-year cumulative risk for clinically diagnosed ON was 1.6% (SE 0.4). The incidence was significantly higher among females (p=0.01) and older patients, with a peak rate of 7.4% (2.3) among those aged 10 to 17 years (p

Original languageEnglish
Pages (from-to)747-753
Number of pages7
JournalHaematologica
Volume88
Issue number7
Publication statusPublished - Jul 1 2003

Fingerprint

Osteonecrosis
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Drug Therapy
Steroids
Incidence
Prednisone
Combination Drug Therapy
Dexamethasone

Keywords

  • Acute lymphoblastic leukemia
  • Dexamethasone
  • Osteonecrosis

ASJC Scopus subject areas

  • Hematology

Cite this

Aricò, M., Pinta Boccalatte, M. F., Silvestri, D., Barisone, E., Messina, C., Chiesa, R., ... De Rossi, G. (2003). Osteonecrosis: An emerging complication of intensive chemotherapy for childhood acute lymphoblastic leukemia. Haematologica, 88(7), 747-753.

Osteonecrosis : An emerging complication of intensive chemotherapy for childhood acute lymphoblastic leukemia. / Aricò, Maurizio; Pinta Boccalatte, Marie France; Silvestri, Daniela; Barisone, Elena; Messina, Chiara; Chiesa, Robert; Santoro, Nicola; Tamaro, Paolo; Lippi, Alma; Gallisai, Domenico; Basso, Giuseppe; De Rossi, Giulio.

In: Haematologica, Vol. 88, No. 7, 01.07.2003, p. 747-753.

Research output: Contribution to journalArticle

Aricò, M, Pinta Boccalatte, MF, Silvestri, D, Barisone, E, Messina, C, Chiesa, R, Santoro, N, Tamaro, P, Lippi, A, Gallisai, D, Basso, G & De Rossi, G 2003, 'Osteonecrosis: An emerging complication of intensive chemotherapy for childhood acute lymphoblastic leukemia', Haematologica, vol. 88, no. 7, pp. 747-753.
Aricò M, Pinta Boccalatte MF, Silvestri D, Barisone E, Messina C, Chiesa R et al. Osteonecrosis: An emerging complication of intensive chemotherapy for childhood acute lymphoblastic leukemia. Haematologica. 2003 Jul 1;88(7):747-753.
Aricò, Maurizio ; Pinta Boccalatte, Marie France ; Silvestri, Daniela ; Barisone, Elena ; Messina, Chiara ; Chiesa, Robert ; Santoro, Nicola ; Tamaro, Paolo ; Lippi, Alma ; Gallisai, Domenico ; Basso, Giuseppe ; De Rossi, Giulio. / Osteonecrosis : An emerging complication of intensive chemotherapy for childhood acute lymphoblastic leukemia. In: Haematologica. 2003 ; Vol. 88, No. 7. pp. 747-753.
@article{3bd5bfefae8f454c8f9134eb69dc61da,
title = "Osteonecrosis: An emerging complication of intensive chemotherapy for childhood acute lymphoblastic leukemia",
abstract = "Background and Objectives. Osteonecrosis (ON) is a potentially disabling complication of combination chemotherapy including high doses of steroids. The incidence and main risk factors for symptomatic ON have been investigated in a large group of children treated with high-dose steroids, prednisone and dexamethasone for childhood acute lymphoblastic leukemia (ALL). Design and Methods. From May 1995 to December 1999, 1421 patients <18 years old, with newly diagnosed non-B ALL, were registered in the AIEOP-ALL 95 study. Their data were reviewed to identify patients who developed symptomatic ON. For those who were positively identified additional data were requested concerning ON-related symptoms, treatment and outcome. Results. Overall, 15 of the 1421 patients developed symptomatic ON (1.1{\%}) in a total of 29 sites. The estimated 5-year cumulative risk for clinically diagnosed ON was 1.6{\%} (SE 0.4). The incidence was significantly higher among females (p=0.01) and older patients, with a peak rate of 7.4{\%} (2.3) among those aged 10 to 17 years (p",
keywords = "Acute lymphoblastic leukemia, Dexamethasone, Osteonecrosis",
author = "Maurizio Aric{\`o} and {Pinta Boccalatte}, {Marie France} and Daniela Silvestri and Elena Barisone and Chiara Messina and Robert Chiesa and Nicola Santoro and Paolo Tamaro and Alma Lippi and Domenico Gallisai and Giuseppe Basso and {De Rossi}, Giulio",
year = "2003",
month = "7",
day = "1",
language = "English",
volume = "88",
pages = "747--753",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "7",

}

TY - JOUR

T1 - Osteonecrosis

T2 - An emerging complication of intensive chemotherapy for childhood acute lymphoblastic leukemia

AU - Aricò, Maurizio

AU - Pinta Boccalatte, Marie France

AU - Silvestri, Daniela

AU - Barisone, Elena

AU - Messina, Chiara

AU - Chiesa, Robert

AU - Santoro, Nicola

AU - Tamaro, Paolo

AU - Lippi, Alma

AU - Gallisai, Domenico

AU - Basso, Giuseppe

AU - De Rossi, Giulio

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Background and Objectives. Osteonecrosis (ON) is a potentially disabling complication of combination chemotherapy including high doses of steroids. The incidence and main risk factors for symptomatic ON have been investigated in a large group of children treated with high-dose steroids, prednisone and dexamethasone for childhood acute lymphoblastic leukemia (ALL). Design and Methods. From May 1995 to December 1999, 1421 patients <18 years old, with newly diagnosed non-B ALL, were registered in the AIEOP-ALL 95 study. Their data were reviewed to identify patients who developed symptomatic ON. For those who were positively identified additional data were requested concerning ON-related symptoms, treatment and outcome. Results. Overall, 15 of the 1421 patients developed symptomatic ON (1.1%) in a total of 29 sites. The estimated 5-year cumulative risk for clinically diagnosed ON was 1.6% (SE 0.4). The incidence was significantly higher among females (p=0.01) and older patients, with a peak rate of 7.4% (2.3) among those aged 10 to 17 years (p

AB - Background and Objectives. Osteonecrosis (ON) is a potentially disabling complication of combination chemotherapy including high doses of steroids. The incidence and main risk factors for symptomatic ON have been investigated in a large group of children treated with high-dose steroids, prednisone and dexamethasone for childhood acute lymphoblastic leukemia (ALL). Design and Methods. From May 1995 to December 1999, 1421 patients <18 years old, with newly diagnosed non-B ALL, were registered in the AIEOP-ALL 95 study. Their data were reviewed to identify patients who developed symptomatic ON. For those who were positively identified additional data were requested concerning ON-related symptoms, treatment and outcome. Results. Overall, 15 of the 1421 patients developed symptomatic ON (1.1%) in a total of 29 sites. The estimated 5-year cumulative risk for clinically diagnosed ON was 1.6% (SE 0.4). The incidence was significantly higher among females (p=0.01) and older patients, with a peak rate of 7.4% (2.3) among those aged 10 to 17 years (p

KW - Acute lymphoblastic leukemia

KW - Dexamethasone

KW - Osteonecrosis

UR - http://www.scopus.com/inward/record.url?scp=0038038460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038038460&partnerID=8YFLogxK

M3 - Article

C2 - 12857552

AN - SCOPUS:0038038460

VL - 88

SP - 747

EP - 753

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 7

ER -